- Home
- BGLC vs ADTX Comparison
BGLC vs ADTX Comparison
Compare BGLC & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- ADTX
- Stock Information
- Founded
- BGLC 2017
- ADTX 2017
- Country
- BGLC Malaysia
- ADTX United States
- Employees
- BGLC N/A
- ADTX N/A
- Industry
- BGLC Medical Specialities
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- ADTX Health Care
- Exchange
- BGLC Nasdaq
- ADTX Nasdaq
- Market Cap
- BGLC 5.8M
- ADTX 5.3M
- IPO Year
- BGLC N/A
- ADTX 2020
- Fundamental
- Price
- BGLC $0.29
- ADTX $5.58
- Analyst Decision
- BGLC
- ADTX
- Analyst Count
- BGLC 0
- ADTX 0
- Target Price
- BGLC N/A
- ADTX N/A
- AVG Volume (30 Days)
- BGLC 1.4M
- ADTX 8.1M
- Earning Date
- BGLC 05-14-2025
- ADTX 05-19-2025
- Dividend Yield
- BGLC N/A
- ADTX N/A
- EPS Growth
- BGLC N/A
- ADTX N/A
- EPS
- BGLC N/A
- ADTX N/A
- Revenue
- BGLC $9,259,858.00
- ADTX $133,985.00
- Revenue This Year
- BGLC N/A
- ADTX $95.61
- Revenue Next Year
- BGLC N/A
- ADTX $1,584.79
- P/E Ratio
- BGLC N/A
- ADTX N/A
- Revenue Growth
- BGLC N/A
- ADTX N/A
- 52 Week Low
- BGLC $0.21
- ADTX $4.11
- 52 Week High
- BGLC $1.00
- ADTX $35,000.00
- Technical
- Relative Strength Index (RSI)
- BGLC 45.41
- ADTX 35.33
- Support Level
- BGLC $0.23
- ADTX $4.17
- Resistance Level
- BGLC $0.29
- ADTX $7.69
- Average True Range (ATR)
- BGLC 0.03
- ADTX 1.71
- MACD
- BGLC -0.00
- ADTX 0.45
- Stochastic Oscillator
- BGLC 47.67
- ADTX 16.69
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.